intelligent omics limited Company Information
Company Number
06500709
Website
compandx.artisteer.netRegistered Address
biocity nottingham, pennyfoot street, nottingham, NG1 1GF
Industry
Research and experimental development on biotechnology
Telephone
03333231843
Next Accounts Due
September 2025
Group Structure
View All
Shareholders
nottingham trent university 49.1%
robert rees 13.7%
View Allintelligent omics limited Estimated Valuation
Pomanda estimates the enterprise value of INTELLIGENT OMICS LIMITED at £333.4k based on a Turnover of £261k and 1.28x industry multiple (adjusted for size and gross margin).
intelligent omics limited Estimated Valuation
Pomanda estimates the enterprise value of INTELLIGENT OMICS LIMITED at £695.9k based on an EBITDA of £133.2k and a 5.22x industry multiple (adjusted for size and gross margin).
intelligent omics limited Estimated Valuation
Pomanda estimates the enterprise value of INTELLIGENT OMICS LIMITED at £444.6k based on Net Assets of £208.4k and 2.13x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Intelligent Omics Limited Overview
Intelligent Omics Limited is a live company located in nottingham, NG1 1GF with a Companies House number of 06500709. It operates in the research and experimental development on biotechnology sector, SIC Code 72110. Founded in February 2008, it's largest shareholder is nottingham trent university with a 49.1% stake. Intelligent Omics Limited is a established, micro sized company, Pomanda has estimated its turnover at £261k with high growth in recent years.
Upgrade for unlimited company reports & a free credit check
Intelligent Omics Limited Health Check
Pomanda's financial health check has awarded Intelligent Omics Limited a 3.5 rating. We use a traffic light system to show it exceeds the industry average on 4 measures and has 5 areas for improvement. Company Health Check FAQs
4 Strong
2 Regular
5 Weak
Size
annual sales of £261k, make it smaller than the average company (£4.2m)
- Intelligent Omics Limited
£4.2m - Industry AVG
Growth
3 year (CAGR) sales growth of 27%, show it is growing at a faster rate (14.3%)
- Intelligent Omics Limited
14.3% - Industry AVG
Production
with a gross margin of 55%, this company has a comparable cost of product (55%)
- Intelligent Omics Limited
55% - Industry AVG
Profitability
an operating margin of 50.6% make it more profitable than the average company (-5.5%)
- Intelligent Omics Limited
-5.5% - Industry AVG
Employees
with 3 employees, this is below the industry average (53)
3 - Intelligent Omics Limited
53 - Industry AVG
Pay Structure
on an average salary of £82.9k, the company has an equivalent pay structure (£82.9k)
- Intelligent Omics Limited
£82.9k - Industry AVG
Efficiency
resulting in sales per employee of £87k, this is less efficient (£131.9k)
- Intelligent Omics Limited
£131.9k - Industry AVG
Debtor Days
it gets paid by customers after 1 days, this is earlier than average (53 days)
- Intelligent Omics Limited
53 days - Industry AVG
Creditor Days
its suppliers are paid after 508 days, this is slower than average (62 days)
- Intelligent Omics Limited
62 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- Intelligent Omics Limited
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 2 weeks, this is less cash available to meet short term requirements (32 weeks)
2 weeks - Intelligent Omics Limited
32 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 86.6%, this is a higher level of debt than the average (52.2%)
86.6% - Intelligent Omics Limited
52.2% - Industry AVG
INTELLIGENT OMICS LIMITED financials
Intelligent Omics Limited's latest turnover from December 2023 is estimated at £261 thousand and the company has net assets of £208.4 thousand. According to their latest financial statements, Intelligent Omics Limited has 3 employees and maintains cash reserves of £18 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Feb 2010 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Turnover | |||||||||||||||
Other Income Or Grants | |||||||||||||||
Cost Of Sales | |||||||||||||||
Gross Profit | |||||||||||||||
Admin Expenses | |||||||||||||||
Operating Profit | |||||||||||||||
Interest Payable | |||||||||||||||
Interest Receivable | |||||||||||||||
Pre-Tax Profit | |||||||||||||||
Tax | |||||||||||||||
Profit After Tax | |||||||||||||||
Dividends Paid | |||||||||||||||
Retained Profit | |||||||||||||||
Employee Costs | |||||||||||||||
Number Of Employees | 3 | 3 | 2 | 1 | 1 | 1 | |||||||||
EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Feb 2010 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Tangible Assets | 1,153 | 2,306 | 3,713 | 4,501 | 6,355 | 1,446 | 75 | 0 | 0 | 789 | 1,481 | 0 | 851 | 1,564 | 818 |
Intangible Assets | 1,475,171 | 1,195,421 | 864,232 | 664,031 | 708,252 | 623,002 | 569,722 | 5,070,626 | 5,070,626 | 3,909,923 | 2,251,895 | 1,185,010 | 143,520 | 68,031 | 11,356 |
Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 349 | 349 | 449 | 0 | 0 | 0 |
Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Fixed Assets | 1,476,324 | 1,197,727 | 867,945 | 668,532 | 714,607 | 624,448 | 569,797 | 5,070,626 | 5,070,626 | 3,911,061 | 2,253,725 | 1,185,459 | 144,371 | 69,595 | 12,174 |
Stock & work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Trade Debtors | 1,287 | 53,684 | 58,100 | 16,000 | 2,700 | 49,996 | 83,314 | 900 | 0 | 193,278 | 175,749 | 168,761 | 22,716 | 18,475 | 2,525 |
Group Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Misc Debtors | 57,266 | 95,547 | 49,286 | 25,234 | 40,195 | 27,129 | 105,030 | 1,819,758 | 137,206 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash | 18,040 | 3,794 | 116,905 | 51,502 | 2,526 | 97,311 | 102,674 | 3,700 | 16,919 | 1,961 | 108,210 | 31,830 | 35,415 | 140,495 | 109,263 |
misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 19,136 | 0 | 0 | 0 | 0 | 0 |
total current assets | 76,593 | 153,025 | 224,291 | 92,736 | 45,421 | 174,436 | 291,018 | 1,824,358 | 154,125 | 214,375 | 283,959 | 200,591 | 58,131 | 158,970 | 111,788 |
total assets | 1,552,917 | 1,350,752 | 1,092,236 | 761,268 | 760,028 | 798,884 | 860,815 | 6,894,984 | 5,224,751 | 4,125,436 | 2,537,684 | 1,386,050 | 202,502 | 228,565 | 123,962 |
Bank overdraft | 3,006 | 3,006 | 1,732 | 1,732 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Trade Creditors | 163,546 | 104,820 | 2,134 | 74,015 | 0 | 20,487 | 5,043 | 7,880 | 0 | 2,662,857 | 435,937 | 748,619 | 61,297 | 21,253 | 16,171 |
Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other current liabilities | 202,420 | 98,486 | 45,549 | 424,171 | 840,842 | 825,095 | 811,728 | 4,244,195 | 3,184,615 | 0 | 0 | 0 | 0 | 0 | 0 |
total current liabilities | 368,972 | 206,312 | 49,415 | 499,918 | 840,842 | 845,582 | 816,771 | 4,252,075 | 3,184,615 | 2,662,857 | 435,937 | 748,619 | 61,297 | 21,253 | 16,171 |
loans | 4,171 | 7,141 | 11,384 | 13,116 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 220,671 | 199,999 | 0 |
hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accruals and Deferred Income | 0 | 0 | 167,722 | 0 | 0 | 0 | 0 | 0 | 0 | 68,711 | 1,127,823 | 21,986 | 0 | 0 | 0 |
other liabilities | 971,341 | 1,027,616 | 829,411 | 300,296 | 0 | 0 | 0 | 2,718,018 | 2,073,313 | 1,444,695 | 925,507 | 575,822 | 0 | 0 | 125,000 |
provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
total long term liabilities | 975,512 | 1,034,757 | 1,008,517 | 313,412 | 0 | 0 | 0 | 2,718,018 | 2,073,313 | 1,513,406 | 2,053,330 | 597,808 | 220,671 | 199,999 | 125,000 |
total liabilities | 1,344,484 | 1,241,069 | 1,057,932 | 813,330 | 840,842 | 845,582 | 816,771 | 6,970,093 | 5,257,928 | 4,176,263 | 2,489,267 | 1,346,427 | 281,968 | 221,252 | 141,171 |
net assets | 208,433 | 109,683 | 34,304 | -52,062 | -80,814 | -46,698 | 44,044 | -75,109 | -33,177 | -50,827 | 48,417 | 39,623 | -79,466 | 7,313 | -17,209 |
total shareholders funds | 208,433 | 109,683 | 34,304 | -52,062 | -80,814 | -46,698 | 44,044 | -75,109 | -33,177 | -50,827 | 48,417 | 39,623 | -79,466 | 7,313 | -17,209 |
Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Feb 2010 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Activities | |||||||||||||||
Operating Profit | |||||||||||||||
Depreciation | 1,153 | 2,126 | 2,543 | 4,502 | 6,355 | 1,521 | 75 | 0 | 789 | 2,269 | 1,481 | 0 | 0 | ||
Amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Tax | |||||||||||||||
Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Debtors | -90,678 | 41,845 | 66,152 | -1,661 | -34,230 | -111,219 | -1,632,314 | 1,683,452 | -56,072 | 17,529 | 6,988 | 146,045 | 4,241 | 18,475 | 2,525 |
Creditors | 58,726 | 102,686 | -71,881 | 74,015 | -20,487 | 15,444 | -2,837 | 7,880 | -2,662,857 | 2,226,920 | -312,682 | 687,322 | 40,044 | 21,253 | 16,171 |
Accruals and Deferred Income | 103,934 | -114,785 | -210,900 | -416,671 | 15,747 | 13,367 | -3,432,467 | 1,059,580 | 3,115,904 | -1,059,112 | 1,105,837 | 21,986 | 0 | 0 | 0 |
Deferred Taxes & Provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash flow from operations | |||||||||||||||
Investing Activities | |||||||||||||||
capital expenditure | |||||||||||||||
Change in Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -349 | 0 | -100 | 449 | 0 | 0 | 0 |
cash flow from investments | |||||||||||||||
Financing Activities | |||||||||||||||
Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long term loans | -2,970 | -4,243 | -1,732 | 13,116 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -220,671 | 20,672 | 199,999 | 0 |
Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other long term liabilities | -56,275 | 198,205 | 529,115 | 300,296 | 0 | 0 | -2,718,018 | 644,705 | 628,618 | 519,188 | 349,685 | 575,822 | 0 | 0 | 125,000 |
share issue | |||||||||||||||
interest | |||||||||||||||
cash flow from financing | |||||||||||||||
cash and cash equivalents | |||||||||||||||
cash | 14,246 | -113,111 | 65,403 | 48,976 | -94,785 | -5,363 | 98,974 | -13,219 | 14,958 | -106,249 | 76,380 | -3,585 | -105,080 | 140,495 | 109,263 |
overdraft | 0 | 1,274 | 0 | 1,732 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
change in cash | 14,246 | -114,385 | 65,403 | 47,244 | -94,785 | -5,363 | 98,974 | -13,219 | 14,958 | -106,249 | 76,380 | -3,585 | -105,080 | 140,495 | 109,263 |
intelligent omics limited Credit Report and Business Information
Intelligent Omics Limited Competitor Analysis
Perform a competitor analysis for intelligent omics limited by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other micro companies, companies in NG1 area or any other competitors across 12 key performance metrics.
intelligent omics limited Ownership
INTELLIGENT OMICS LIMITED group structure
Intelligent Omics Limited has no subsidiary companies.
Ultimate parent company
INTELLIGENT OMICS LIMITED
06500709
intelligent omics limited directors
Intelligent Omics Limited currently has 4 directors. The longest serving directors include Professor Graham Ball (Aug 2009) and Dr Simon Haworth (Mar 2012).
officer | country | age | start | end | role |
---|---|---|---|---|---|
Professor Graham Ball | 54 years | Aug 2009 | - | Director | |
Dr Simon Haworth | United Kingdom | 63 years | Mar 2012 | - | Director |
Dr William Mason | Uk | 73 years | Aug 2018 | - | Director |
Mr Robert Grundy | Northern Ireland | 49 years | May 2023 | - | Director |
P&L
December 2023turnover
261k
-28%
operating profit
132.1k
0%
gross margin
55%
+1.8%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2023net assets
208.4k
+0.9%
total assets
1.6m
+0.15%
cash
18k
+3.75%
net assets
Total assets minus all liabilities
intelligent omics limited company details
company number
06500709
Type
Private limited with Share Capital
industry
72110 - Research and experimental development on biotechnology
incorporation date
February 2008
age
16
incorporated
UK
ultimate parent company
accounts
Total Exemption Full
last accounts submitted
December 2023
previous names
intelligent omics limited (March 2019)
compandx limited (March 2019)
accountant
-
auditor
-
address
biocity nottingham, pennyfoot street, nottingham, NG1 1GF
Bank
-
Legal Advisor
-
intelligent omics limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 1 charges/mortgages relating to intelligent omics limited. Currently there are 1 open charges and 0 have been satisfied in the past.
intelligent omics limited Companies House Filings - See Documents
date | description | view/download |
---|